A new randomized, double-blind, placebo-controlled human trial is the latest in a long list of studies to lend evidence to the possible cardiac benefits of CoEnzyme Q10 supplementation. The study, published in the July issue of the European Heart Journal, found that supplementation with CoEnzyme Q10 (CoQ10) may boost a naturally occurring antioxidant enzyme that supports vein health and that it may improve endothelial function in coronary artery disease patients.¹

Coronary artery disease is the build-up of plaques in the arteries that supply blood to the heart. Coronary artery disease reduces the extracellular levels of superoxide dismutase, an important antioxidant enzyme system of the blood vessels. Researchers selected 38 coronary artery disease patients for the study and gave half of patients 300mg of CoQ10 daily or a placebo daily for one month. At the onset of the study and after one month of intervention, all patients involved in the study underwent brachial artery ED assessment, cardiopulmonary exercise test, and the measurement of endothelium-bound superoxide dismutase activity. The test revealed that those in the group which received the CoQ10 had significantly more superoxide dismutase than those who received the placebo. They had significantly better endothelium-dependent vasodilation (meaning improved blood flow to the heart), and greater peak VO₂ and O₂ blood levels. The researchers noted that there was "remarkable" improvement seen among patients who initial presented low endothelium-bound superoxide dismutase and received CoQ10.

CoEnzyme Q10 has been linked to numerous health benefits in previous studies learn more about CoEnzyme Q10 here.

1. Tiano, L., R. Belardinelli, et al. (2007). "Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study." Eur Heart J.